CRISPR Therapeutics AG (CRSP) Other Non-Current Liabilities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Other Non-Current Liabilities across 12 years of filings, most recently posting $5.9 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $5.9 million, up 79.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.9 million (up 79.16% YoY), and the FY2025 annual result was $6.1 million, up 78.34% from the prior year.
• Other Non-Current Liabilities came in at $5.9 million for Q1 2026 at CRISPR Therapeutics AG, down from $6.1 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $7.3 million in Q1 2022 to a low of $958000.0 in Q4 2023.
• The 5-year median for Other Non-Current Liabilities is $5.3 million (2022), against an average of $4.8 million.
• Across the five-year window, Other Non-Current Liabilities sank 83.95% in 2023 and jumped 259.5% in 2024, its largest moves.
• CRISPR Therapeutics AG's Other Non-Current Liabilities stood at $6.0 million in 2022, then tumbled by 83.95% to $958000.0 in 2023, then surged by 259.5% to $3.4 million in 2024, then soared by 78.34% to $6.1 million in 2025, then retreated by 3.16% to $5.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $5.9 million (Q1 2026), $6.1 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.